*EMBARGOED All research presented at the World Congress of Gastroenterology at ACG2017 is strictly embargoed until Monday, October 16, 2017, at 8:00 am EDT.
Poster 1078 Developing a Screening Test for Barrett’s Esophagus Using Electronic Nose Device Analysis of Exhaled Volatile Organic Compounds
Author Insight from Kavel Visrodia, MD, Mayo Clinic
What’s new here and important for clinicians?
Although patients with Barrett’s esophagus (BE) (the only known precursor of esophageal adenocarcinoma) undergo surveillance, more than 90% of esophageal adenocarcinomas are diagnosed outside of surveillance programs, suggesting current screening and surveillance programs are inadequate. In an effort to develop a highly acceptable, less-expensive screening method, we piloted the use of a non-invasive, highly portable electronic nose device to detect BE from breath samples. Based on analysis of 58 breath samples, the predictive model for BE was associated with 89% sensitivity, 71% specificity, 79% accuracy, area under the curve 0.81, positive predictive value 0.73, and negative predictive value 0.88.
What do patients need to know?
Electronic-nose technology provides good discrimination between persons with BE and those without BE. The high-sensitivity, low-cost, non-invasive nature of electronic nose testing, and high rate of patient usage, suggest it can be used as a screening tool to identify patients with BE for further surveillance. However, further work to refine the model and improve the test’s efficiency is ongoing.
Kavel Visrodia, MD, Mayo Clinic
Media Interview Requests:
To arrange an interview with any ACG experts or abstract authors, please contact Brian Davis of ACG via email at email@example.com or by phone at 301-263-9000.